# A higher efficient in vitro functional assay for anti-epileptic drug discovery

Lulan Chen, Jian Xu, Shuzhang Zhang, Pin Ye\*, Ruiben Feng\*, Department of Biological Pharmacology, Chempartner, Inc. China

# Introduction

Rodent brain slice assay has been regarded as the "gold standard" of ex vivo preclinical evaluation and screening for CNS drug discovery. However, this conventional electrophysiology technique has very limited throughput in screening large numbers of compounds. For the purpose to facilitate antiepileptic drugs screening using ex vivo tissue-based models, an in vitro cell-based epileptic model with the application of multiwell Microelectrode Arrays (mwMEA) has been developed.

We reported here is an application of the mwMEA as a high-throughput, automated assay that captures the electrical activity of adherent, excitable cell populations, which is suitable for non-invasive, long-term in vitro experiments. Establishment of an In vitro cell-based epileptic MEA assay could offer a new avenue for the evaluation and high-throughput screening of pro-epileptic or antiepileptic drug candidates.

#### Results



### Methods



The underlying mechanism of epilepsy involves an imbalance between inhibitory and excitatory effects. In this study, based on primary hippocampal neurons cultured on mwMEA plates, pro-seizurogenic compounds with different mechanisms (Picrotoxin, 4traditional

Figure 2: Increase of synchronized burst firing after treatment of various seizurogenic compounds were attenuated by an increase in VPA concentration.



Aminopyridine, Pentylenetetrazol) and elevated extracellular K<sup>+</sup> concentration were used to establish *in vitro* seizurogenic models, followed by the evaluation of anti-seizurogenic effects of Valproate or Retigabine acting on different targets.

#### **Seizurogenic compounds:**

#### **Anti-Seizurogenic compounds:**

Picrotoxin (Pic): a non-competitive antagonist of GABA<sub>A</sub> receptors ●Valproate (VPA): an enhancer of •Pentylenetetrazol (PTZ): an antagonist of GABA<sub>A</sub> receptors and GABAergic transmission and blocker of enhancer of influx of Ca<sup>2+</sup> and Na<sup>+</sup> into neurons voltage-gated sodium channels •4-Aminopyridine (4-AP): an inhibitor of voltage-gated potassium •Retigabine (RTG): primary as an channel

activator of KCNQ channel and also a

•High K<sup>+</sup>: Elevation of extracellular potassium levels to 6.5 mM

modulator of GABA<sub>A</sub> receptor.

## Results

#### In vitro functional assay for anti-seizure-like discharge drug discovery



Figure 3: Increase of synchronized burst treatment of various seizurogenic compounds were attenuated and inhibited by an increase in retigabine concentration.

#### Primary hippocampal neurons recorded by patch clamp

#### KCNQ2 stable cell lines recorded by patch clamp



Figure 4: Evoked action potential could be reversibly suppressed by the activation of KCNQ channels mediated by retigabine.

## Conclusions

- The in vitro cell-based seizurogenic models have been successfully established using various methods, including the application of picrotoxin, pentetrazol (PTZ), 4-aminopyridine (4-AP), or by increasing the extracellular potassium concentration (6.5 mM K<sup>+</sup>).
- Valproate or Retigabine has shown a dose-dependent anti-seizurogenic effect on these *in vitro* cell-based seizurogenic models via attenuating the synchronized network ictal burst firing pattern and decreasing the frequency of interictal spike firing.
- □ The mwMEA based rat hippocampal neuronal seizurogenic assay is sensitive to identify a range of changes in neuronal firing activity and firing pattern caused by several seizurogenic or anti-seizurogenic compounds with known mechanisms. □ In vitro cell based mwMEA platform in combination with patch clamp platform can provide a strategy for anti-seizurogenic drug screening. This approach spans from ion channels in stably expressed cell lines to single or population primary neurons, such as targeting the KCNQ channel.